May result in changes in uptake of PIFLUFOLASTAT F-18 in prostate cancer. Effect on PET performance not established.
Source: NLP:piflufolastat f-18
Piflufolastat F-18 Interactions
Brand names: Pylarify
Radioactive Diagnostic Agent · Positron Emitting Activity
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary PYLARIFY is not indicated for use in females. There is no information on the risk of adverse developmental outcomes in pregnant women or animals with the use of piflufolastat F 18. All radiopharmaceuticals, including PYLARIFY, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
2 interactions on record
May result in changes in uptake of PIFLUFOLASTAT F-18 in prostate cancer. Effect on PET performance not established.
Source: NLP:piflufolastat f-18